Versartis (VSAR) – Investment Analysts’ Recent Ratings Updates

Versartis (NASDAQ: VSAR) has recently received a number of price target changes and ratings updates:

  • 9/8/2017 – Versartis had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $26.00 price target on the stock.
  • 9/1/2017 – Versartis was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/30/2017 – Versartis was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. “
  • 8/23/2017 – Versartis had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $45.00 price target on the stock.
  • 8/17/2017 – Versartis was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/2/2017 – Versartis was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. “
  • 8/2/2017 – Versartis was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/28/2017 – Versartis was given a new $28.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/27/2017 – Versartis was given a new $34.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/24/2017 – Versartis was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/16/2017 – Versartis was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of Versartis, Inc. (NASDAQ VSAR) traded down 9.38% on Tuesday, hitting $18.35. 730,994 shares of the stock traded hands. Versartis, Inc. has a 12-month low of $9.05 and a 12-month high of $24.00. The stock has a 50-day moving average price of $18.35 and a 200 day moving average price of $18.48. The stock’s market cap is $652.86 million.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.20). On average, analysts anticipate that Versartis, Inc. will post ($3.49) earnings per share for the current fiscal year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.